THE CAUDAL REGIONS of the nucleus of the solitary tract (NTS) have been identified as the primary central termination site of arterial chemoreceptor afferents (4-6, 15, 36) . In the rat, electrical or chemical activation of the caudal NTS (cNTS), ϳ600 m caudal to the most caudal tip of area postrema, elicits a rapid increase in sympathetic drive, blood pressure, and respiratory rate (25, 36) , a response similar to that evoked by direct activation of arterial chemoreceptors (16, 36) . Conversely, electrolytic lesions or chemical blockade of the cNTS selectively attenuates chemoreflex responses (27, 36, 38) . Although the cNTS and other critical regions of the brain, including the rostral ventrolateral medulla and the ventrolateral pons, have been identified to be essential components of the central arterial chemoreflex pathway (17) (18) (19) 29) , surprisingly little is known about the neurochemicals important in modulating this central reflex arc.
Present evidence suggests that glutamate may be the primary neurotransmitter released by chemoreceptor afferents to activate second-order neurons in the NTS (10, 36, 38) . There is also evidence that release of norepinephrine within the cNTS may be important to central processing of arterial chemoreceptor inputs. First, the cNTS is richly innervated by noradrenergic neurons, originating from both within the NTS (A2), the ventrolateral medulla (A1), and the ventrolateral pons (A5) (21, 35) . Second, immunohistochemical studies have shown that brief exposure to hypoxia in rats activates noradrenergic neurons in the A1 and A5 regions that may potentially project to the cNTS (5, 14) , and, finally, changes in norepinephrine release and biosynthesis have been documented in the cNTS following prolonged exposure to hypoxia (28, 31, 32) . Therefore, there is good evidence to suggest that norepinephrine may be an important neuromodulator of chemoreceptor afferent processing in the cNTS. The functional implication of modulating norepinephrine levels or ␣-2 receptor function in the cNTS on arterial chemoreflex function, however, remains to be fully defined.
The present study was undertaken to identify the effects of ␣-2 adrenoreceptor blockade in the cNTS on arterial chemoreflex function. On the basis of previous findings that norepinephrine is an important neuromodulator of visceral afferent processing in other regions of the NTS, including arterial baroreflex function (20, 33) , in the present study it was hypothesized that blockade of the ␣-2 adrenoreceptors in cNTS would significantly attenuate chemoreflex function. The results of this study confirm this hypothesis. Portions of this work have been presented in a preliminary format (11) .
METHODS
All experiments were performed on adult male SpragueDawley rats (320-420 g; obtained from Harlan) housed in the university animal care facility and exposed to a normal 12:12-h light-dark cycle (6 AM to 6 PM and 6 PM to 6 AM).
All experimental procedures were preapproved by the University of Florida Institutional Animal Care and Use Committee.
General preparation. Animals were anesthetized with an intraperitoneal injection of urethane (1.2-1.4 g/kg) and instrumented with femoral arterial and venous catheters (PE-50 tubing) for recording of arterial pressure and administration of intravenous fluids, respectively. While the rat was in the supine position, a midline incision was made on the ventral surface of the neck, a tracheostomy was performed, and the animal was intubated. Two small (0.003-mm diameter) Teflon-coated, stainless steel wires with bared tips were inserted into the right side of the diaphragm through the abdominal musculature for measurement of inspiratory activity. Next, the renal nerve was exposed retroperitoneally, isolated, and covered with warmed mineral oil. The animal was placed in the prone position in a stereotaxic head holder (Kopf, Tugunga, CA), and the dorsal surface of the medulla was exposed by a limited craniotomy and removal of the atlantooccipital membrane.
The arterial catheter was attached to a calibrated pressure transducer (Statham) connected to an amplifier (Stoelting). The analog output from the blood pressure amplifier was connected to a computer data-sampling system [Cambridge Electronics Design (CED), 1401 computer interface]. The intact branch of the renal nerve was placed on a bipolar silver wire electrode attached to a Grass preamplifier probe (H1P1) and signal amplifier (P511). The diaphragm electromyographic (dEMG) wires were connected to a second Grass preamplifier probe and P511 amplifier. Both dEMG and renal sympathetic nerve activity (RSNA) signals were amplified (200,000 to 500,000 times), band-pass filtered (0.3 to 1.0 kHz), rectified, and integrated (50-to 20-ms time constants, respectively; Paynter Filter, BAK Electronics). Rectified and integrated dEMG and RSNA signals were then connected to the CED system. Baseline dEMG and RSNA amplitudes were arbitrarily adjusted to a value of 2.0-2.5 (arbitrary U) at the beginning of the experiment and recorded simultaneously along with arterial pressure. Body temperature was kept within normal range of 38 Ϯ 1°C with a heating blanket and a rectal temperature probe (Harvard Apparatus). Supplemental anesthesia was given when necessary (0.1 g/kg iv), as evidenced by marked changes in blood pressure, heart rate (HR), or respiration during surgery or in response to a pinch of the hindpaw.
In some experiments, animals were vagotomized (vagal nerves were isolated and sectioned bilaterally in the cervical region), paralyzed, and ventilated. Before administration of the paralytic (20 mg/kg pancuronium bromide), animals were mechanically ventilated (Harvard Small Animal Ventilator). Mechanical ventilation rate was set between 65 and 75 breaths/min. The paralytic was then administered, and absence of dEMG was used as an indicator of the effectiveness of the paralytic. With the return of dEMG activity, an additional dose of the paralytic was given. In all animals, reflex testing typically took place 2 h following the initial induction of anesthesia.
Protocol. In the present set of experiments, arterial chemoreflex responses were elicited by intravenous bolus injections of potassium cyanide (KCN; 75 g/kg). The intertrial interval for KCN administration was ϳ10 min. KCN was chosen as a stimulus because it provides a brief potent stimulus for arterial chemoreceptors and elicits reproducible reflex responses when repeated administration occurs at 5-to 10-min intervals (12, 13, 18) .
Baroreflex responses were also recorded by monitoring RSNA and HR in response to intravenous bolus injections of phenylephrine (PE; 20-30 g/kg). The testing of baroreflex responses occurred in separate trials from chemoreflex testing. Intravenous PE injections were administered ϳ5 min following each KCN injection and 10 min following the preceding PE injection. All data were collected during 90-s trials, during which time blood pressure, dEMG, and RSNA were sampled continuously for 20 s before and 70 s following intravenous drug administration.
After the collection of baseline chemoreflex and baroreflex responses (typically, two reflex responses each), a singlebarrel microinjection pipette was attached to a pressure injection system (BH-2, Medical Systems) and secured to a micromanipulator (Kopf). Next, the micropipette was positioned 500-600 m caudal to the most caudal tip of area postrema, Ϯ200 m lateral from midline, and 200-400 m ventral to the surface of the brain. All drugs were diluted in artificial cerebrospinal fluid (aCSF) (in mM): 122 NaCl, 3 KCl, 25.7 NaHCO 3 Ϫ , and 1 CaCl2, with the pH adjusted to 7.4. A small amount of fluorescent latex microspheres (Lumafluor) was added to the aCSF solution to facilitate identification of the microinjection sites. The microinjection pipette was filled with either idazoxan (20 mM; RBI) or yohimbine (2 mM; Sigma), ␣-2 receptor antagonists (9), or kynurenic acid (10 mM; Sigma), a broad-spectrum excitatory amino acid (EAA) receptor antagonist (38) . In separate experiments, aCSF alone was microinjected into the cNTS as a control for potential volume-related effects produced by microinjection process alone.
All solutions were microinjected bilaterally in volumes of 45-65 nl/side. The volume microinjected was determined by carefully monitoring the movement of the meniscus in the micropipette with a monocular microscope equipped with a calibrated eyepiece (Titan Tools). Thirty seconds following completion of the central injections, the micropipette was retracted from the brain. Five minutes following completion of bilateral microinjection, arterial chemoreflex and baroreflex responses were retested. Reflex responses were then retested 90 min following the central microinjection.
At the end of the experiment, the animal was euthanized, and the brain was removed and placed in a 4% paraformaldehyde solution for 24-72 h. The brains were then frozen to Ϫ14°C, and the caudal brain stem was sliced into 40-m transverse sections with a cryostat (Zeiss, HM101), mounted on slides, and sealed with a coverslip (Antifade, Molecular Probes). The microinjection site was then recovered by imaging the brain slices with a microscope equipped with epifluorescence (Zeiss) and a computer-enhanced imaging system (Axiovision).
Data analysis. All data were analyzed offline using SPIKE2 software (CED). Peak changes in mean arterial pressure (MAP) and RSNA during chemoreceptor or baroreceptor stimulation were calculated from the difference between the baseline (a 5-s average measured 10 s before each bolus injection) and the peak deviation from baseline during chemoreceptor or baroreceptor stimulation (a 3-s average). Background noise levels in the RSNA signal were quantified (during baroreflex-evoked inhibition of sympathetic drive elicited by the PE bolus injections) and then subtracted from the total rectified and integrated RSNA signal. Peak changes in RSNA during KCN or PE administration were represented as a percentage change from the immediately preceding baseline. To help maintain consistent measurement time windows between trials, changes in HR were always calculated from within same time window used for calculation of the peak MAP response. HR was derived from the average interval between peak systolic pressure pulses in the arterial pressure trace.
Respiratory parameters, including dEMG burst duration, interburst interval, burst amplitude, and respiratory frequency, were calculated from individual bursts and then averaged. Baseline respiratory activity was averaged over the same 5-s period as MAP, RSNA, and HR (i.e., 10 s before intravenous bolus injections). Peak changes in respiratory parameters were calculated by subtracting the 5-s baseline average from the average peak respiratory reflex response averaged from within one of two consecutive 3-s time windows that began at the onset of a change in respiratory pattern (typically identified by an increase in dEMG burst amplitude; see RESULTS). For baroreflex responses, the peak respiratory response was measured during the same time window used to calculate peak changes in MAP and HR.
Significant changes in chemoreflex or baroreflex responses following central microinjection of idazoxan, yohimbine, kynurenic acid, or aCSF were analyzed using paired Student's t-test with Bonferroni corrections for multiple comparisons. Changes were considered significant when P Ͻ 0.05. All data are means Ϯ SE.
RESULTS
The mean weight of the adult male rats used in this study was 348 Ϯ 5 g (n ϭ 31). In the spontaneously breathing rats, the average resting MAP, HR, and respiratory rates were 100 Ϯ 2 mmHg, 372 Ϯ 7 beats/ min, and 106 Ϯ 3 breaths/min (n ϭ 26), respectively. Figure 1A shows the typical response to intravenous injection of KCN (75 g/kg) observed in a spontaneously breathing animal. The onset of the arterial chemoreflex response was characterized by an increase in the burst amplitude of both RSNA and dEMG and typically began 3 s following the bolus injection of KCN. The initial increase in dEMG amplitude was identified as the first phase of a two-phase respiratory response to KCN injection and was characterized by a peak increase in dEMG amplitude during the first 3 s of onset of the response. This first phase was labeled peak-1 (Pk-1; see Fig. 1 for an example of the Pk-1 time window). The average increase in dEMG burst amplitude during this time was 100 Ϯ 13% (n ϭ 26) above the preceding baseline and was coupled with small initial increase in respiratory rate (Pk-1 mean increase in rate was 29 Ϯ 4 breaths/min; n ϭ 26). But the greatest change in respiratory rate typically occurred during the next 3-s time window following KCN injection. This second phase of the response to KCN was labeled peak-2 (Pk-2; see Fig. 1 for an example of the Pk-2 time window), and the average increase in respiratory rate during Pk-2 was 47 Ϯ 4 breaths/min (n ϭ 26). Peak changes in RSNA occurred during Pk-1 (98 Ϯ 16% above baseline; n ϭ 26), and peak changes in MAP (18 Ϯ 2 mmHg; n ϭ 26) followed the RSNA response. KCN-evoked changes in HR were averaged during the peak change in MAP and were minimal (5 Ϯ 1 beats/ min; n ϭ 26). MAP, HR, and RSNA returned to baseline within 30 s following KCN injections. Respiration rate returned to baseline levels within 60 s following the initial onset of the reflex response.
To identify whether the cardiorespiratory responses described above were indeed associated with KCN stimulation of arterial chemoreceptors, in three animals reflex responses to KCN were recorded before and 10 min following bilateral sectioning of the carotid Fig. 1 . Effect of ␣-2 adrenoreceptor blockade in the caudal region of the nucleus of the solitary tract (cNTS) on the arterial chemoreflex response in a spontaneously breathing, anesthetized rat. Cardiorespiratory responses from a single rat to intravenous injections of potassium cyanide (KCN; 75 g/kg, horizontal black bars) before (A: control) and ϳ5 min following bilateral injection of 2 nmol (total) of the ␣-2 receptor antagonist idazoxan into the cNTS (B: postidazoxan). Arterial pressure (AP; in mmHg), renal sympathetic nerve activity [RSNA; in arbitrary units (AU)], and diaphragm electromyographic activity (dEMG; in AU) responses to KCN were markedly attenuated following ␣-2 receptor blockade. Heart rate [HR; in beats/min (bpm)] response was minimal before and following idazoxan. Peak (Pk)-1 illustrates the time window during which peak changes in dEMG burst amplitude were measured. Pk-2 shows the typical time window in which peak changes in dEMG burst frequency were measured. ଙTime during which the peak AP response to KCN was measured. The preceding rise in AP was associated with the 0.2 ml saline flush used to administer the KCN intravenously. sinus nerves, which contain the primary source of peripheral chemoreceptor afferents in the rat (16) . As illustrated in Fig. 2 , carotid sinus denervation eliminated both cardiovascular and respiratory responses to intravenous KCN. Acute denervation also resulted in a small decrease in resting MAP (82 Ϯ 5 vs. 73 Ϯ 11 mmHg, pre-vs. postdenervation, respectively; n ϭ 3), HR (359 Ϯ 9 vs. 339 Ϯ 17 beats/min), and respiratory rate (101 Ϯ 8 vs. 88 Ϯ 4 breaths/min).
Effects of idazoxan microinjection into the cNTS on arterial chemoreflex and baroreflex responses. To identify the potential role of endogenous catecholamines in the central processing of arterial chemoreceptor input, the ␣-2 receptor antagonist idazoxan (9, 33) was microinjected bilaterally into the cNTS of a group of spontaneously breathing animals (n ϭ 10). As illustrated in Fig. 1B , arterial chemoreflex responses were markedly attenuated following microinjection of a total of 2 nmol of idazoxan into the cNTS. Figures 3 and 4 illustrate the average change in chemoreflex responses recorded before, 5 min, and 90 min following idazoxan microinjection into the cNTS. Peak reflex-evoked changes in both MAP and RSNA were significantly attenuated following idazoxan microinjection (Fig. 3) as were the peak respiratory responses (Pk-1 dEMG burst amplitude and Pk-2 respiratory rate; see Fig. 4 ). There was also a trend for the increase in respiratory rate measured during Pk-1 to be blunted, but the change was not significant (Table 1) . Reflex-evoked changes in HR were minimal before and were not markedly altered following idazoxan microinjection into the cNTS. Idazoxan-induced attenuation of chemoreflex responses was not coupled with any significant change in resting MAP, RSNA, HR, or respiratory rate (Table 2) .
KCN-evoked increases in MAP, RSNA (Fig. 3) , and respiratory rate (Table 1 and Fig. 4B ) returned to control levels at 90 min following central idazoxan microinjection. Similarly, resting respiratory rate, RSNA, and HR (Table 2) were not significantly different from control levels when remeasured at 90 min following cNTS microinjection. In contrast, reflex changes in the Pk-1 dEMG burst amplitude remained significantly attenuated (Fig. 4A) , and resting MAP had declined at 90 min compared with control (Table 2) .
Arterial baroreflex responses were also measured in the same group of animals before and following central idazoxan microinjection. Cardiorespiratory responses to increases in MAP were produced by intravenous PE. The mean increase in MAP elicited by a bolus injection of PE before idazoxan microinjection was 45 Ϯ 12 mmHg and was not significantly different from the mean PE-induced increase in MAP following cNTS idazoxan microinjection (57 Ϯ 7 mmHg; P Ͻ 0.2). Unlike chemoreflex function, microinjection of 2 nmol idazoxan into the cNTS did not significantly alter baroreflex control of RSNA, HR, or respiration (Fig. 5) .
In two animals, bilateral microinjections of 2 nmol idazoxan were made into the region overlying the cNTS (nucleus gracilus; see Fig. 8 ). ␣-2 Receptor blockade in the nucleus gracilus produced no noticeable change in chemoreflex responses. For example, the peak KCNevoked increase in MAP was 15 Ϯ 1 mmHg before microinjection vs. 14 Ϯ 1 mmHg after idazoxan microinjection in the nucleus gracilus. Reflex responses from these two animals were not included in the analysis of those animals described above in which idazoxan microinjections were localized to the cNTS.
Effects of yohimbine in the cNTS on chemoreflex responses in ventilated, vagotomized rats. To identify whether changes in respiratory pattern associated with ␣-2 receptor blockade in the cNTS contributed in any way to the simultaneous attenuation of the cardiovascular response, chemoreflex responses were recorded in a second group of vagotomized, artificially ventilated, and paralyzed animals (n ϭ 5). In these animals, chemoreflex responses were recorded before and after bilateral microinjection of a different ␣-2 receptor antagonist, yohimbine (0.2-nmol total dose), into the cNTS. Similar to the effects of idazoxan, yohimbine microinjected into the cNTS significantly attenuated KCN-evoked increases in MAP and RSNA (Fig. 6A) . HR responses were minimal before and remained unchanged following cNTS yohimbine microinjection. All reflex responses returned to control levels 90 min following central yohimbine microinjection (Fig. 6, B and C) .
Despite a marked attenuation of chemoreflex function following microinjection of yohimbine into the postinjection, respectively) were not altered. When remeasured at 90 min, resting MAP, RSNA, and HR remained unchanged, although there was a trend for MAP to decline over time (108 Ϯ 9 vs. 99 Ϯ 16 mmHg, pre-vs. 90 min postinjection, respectively).
Effects of kynurenic acid in the cNTS. To confirm that our microinjection sites were in the same region of the NTS previously identified to be critical for chemoreceptor afferent processing (36, 39), we tested the effect of bilateral EAA receptor blockade (1 nmol kynurenic acid, total dose) in the cNTS on arterial chemoreflex function in a third group of spontaneously breathing animals (n ϭ 8). Similar to those findings reported by other investigators, 5 min following blockade of EAA receptors in the cNTS, arterial chemoreflex responses were markedly attenuated (Fig. 7) , including a significant decrease in reflex-evoked changes in MAP and RSNA (Fig. 3 ) and a significant reduction in peak dEMG burst amplitude (Pk-1) and respiratory rate (Pk-2; Fig. 4 ). The initial increase in respiratory rate (Pk-1) was also attenuated, but the change was not significant (Table 1) . Reflex-associated changes in HR were minimal before and were not altered following kynurenic acid microinjection. All components of the cardiorespiratory response to KCN (Table 1 and Figs. 3 and 4) returned to control levels when remeasured 90 min following kynurenic microinjection of the cNTS.
Unlike the effect of ␣-2 adrenoreceptor blockade in the cNTS, local blockade of EAA receptors also resulted in a significant reduction in both the resting respiratory rate and HR, yet there was no significant change in resting MAP (Table 2) . By 90 min postkynurenic microinjection, resting HR and respiratory rate had returned to preinjection levels ( Table 2) .
Effects of aCSF in the cNTS on chemoreflex responses. To control for the effects of microinjection alone, in a fourth group of animals chemoreflex responses were tested before and following bilateral microinjections into the cNTS of aCSF (90-to 120-nl total volume). aCSF alone had no effect on resting cardiorespiratory parameters (Table 2) , and neither arterial chemoreflex responses (Figs. 3 and 4 ) nor baroreflex responses (Fig. 5) were significantly altered by aCSF microinjection. Chemoreflex responses retested at 90 min were also unchanged (Table 1 and Figs. 3 and 4) .
Central microinjection sites. Figure 8 shows the reconstructed microinjection sites from all microinjection studies. Histological analysis of the brain stem verified the localization of all microinjection sites within the boundaries of the cNTS, except for the two idazoxan microinjection sites placed in the overlying nucleus gracilus to test the specificity of the microinjection location of reflex function (Fig. 8) .
DISCUSSION
The major finding of this study was that blockade of ␣-2 adrenoreceptors in the region of the cNTS selectively attenuates arterial chemoreflex responses. The effects of ␣-2 adrenoreceptor blockade on the cardiovascular component of the reflex remained in the ventilated animals, suggesting that reflex attenuation by ␣-2 adrenoreceptor antagonists was primarily related to altered chemoreceptor afferent processing in the Fig. 7 . Effect of EAA receptor blockade in the cNTS on arterial chemoreflex responses in a spontaneously breathing, anesthetized rat. Cardiorespiratory responses from a single rat to intravenous bolus injections of KCN (75 g/kg, horizontal black bars) before (A: control) and ϳ5 min following bilateral injection of 1 nmol (total) of the EAA receptor antagonist kynurenic acid into the cNTS (B: post-kynurenic acid). AP (mmHg), RSNA (AU), and dEMG (AU) responses to KCN were markedly attenuated following EAA receptor blockade. Arrows indicate the onset of the reflex response. ଙTime during which the peak AP response to KCN was measured. The preceding rise in AP was associated with the 0.2-ml saline intravenous flush used to administer the KCN. Fig. 8 . Schematic of reconstructed microinjection sites in the cNTS. A: illustration of the dorsal medulla is adapted from Paxinos and Watson (26) . Inset shows a ϫ4 image of fluorescently labeled microinjection sites recovered from 1 animal. ଙCenters of the injection sites marked with rhodamine microspheres. B: F bilateral idazoxan microinjection sites made in the cNTS (n ϭ 10). ଙReconstructed sites from microinjections made in the region nucleus gracilius (gr) in 2 animals. C: ଙbilateral Kyn. Acid microinjection sites (n ϭ 9). D: F bilateral aCSF microinjection sites (n ϭ 6); ଝ 5 reconstructed sites from yohimbine microinjections in the cNTS. Numbers represent the approximate location of the brain region relative to bregma. Ts, solitary tract; Cc, central canal.
cNTS and was not dependent on changes in the respiratory component of the reflex. Consequently, the results of the present study provide the first piece of evidence to suggest that tonic activation of ␣-2 adrenoreceptors in the cNTS may facilitate the central processing of chemoreceptor afferent inputs.
In the present study, KCN was used to briefly stimulate arterial chemoreceptors. Intravenous administration of KCN elicited a rapid increase in respiration rate, dEMG amplitude, RSNA, and MAP, with little change in HR. This response was similar to that reported by other investigators using KCN to elicit chemoreflex responses in urethane-anesthetized rats (8, 30, 36, 38) . Unlike previous studies, however, we characterized the respiratory response to KCN administration as having two components. To our knowledge, this type of analysis has not been previously used to describe the respiratory response to KCN in rats, although a similar biphasic response has previously been noted in conscious animals, but not analyzed as such (8) . Yet, in conscious animals, the phase of increased dEMG frequency was reported to precede the increase in burst amplitude (8) , suggesting that the temporal effects of KCN on respiration that we reported may reflect the combined effects of brief stimulation of the carotid chemoreceptors and the urethane anesthesia. Moreover, the specificity of the cardiovascular and respiratory components of the response to KCN was confirmed by complete elimination of the responses following bilateral denervation of the carotid sinus nerves. This finding is in agreement with the findings of other studies (8, 12, 30) and supports recent data, which suggest that the chemoreflex response in the rat is primarily mediated through carotid chemoreceptor afferents (16) .
A putative role for norepinephrine in the central processing of arterial chemoreceptor afferent input in the cNTS has been suggested for many years by studies demonstrating a link between long-term exposure to hypoxia and altered norepinephrine levels in the cNTS in rats (28, 31, 32) . Furthermore, single-unit recordings from the NTS have identified groups of chemoreceptor afferent-sensitive neurons that are sensitive to local application of catecholamine receptor agonists and antagonists (24) , suggesting chemoreflex function may be altered by ␣-2 adrenoreceptor modulation of chemoreceptor afferent processing within the cNTS. Although previous studies have suggested a role for norepinephrine in the cNTS in the modulation of chemoreflex function, to our knowledge the specific action of norepinephrine or ␣-2 adrenergic receptor modulation within the cNTS on chemoreflex function has not been previously described.
Indeed, prior physiological evidence supporting an important role for catecholamines in the central modulation of the arterial chemoreflex has been relatively sparse. In the early 1980s, pharmacological depletion of both brain and peripheral catecholamines was reported to have little effect on the resting respiratory rate or ventilatory responses to hypoxia in conscious rats (22) . Furthermore, no profound effect on the respiratory component of the arterial chemoreflex has been observed following either intracerebroventricular or intravenous administration of ␣-2 receptor antagonists in rats (1, 3) . Alternatively, intravertebral administration of the adrenoreceptor agonist clonidine has been reported to facilitate chemoreflex-induced vasoconstriction of the hindlimb in anesthetized dogs (34) . Thus it appears that the method of drug delivery and the brain regions targeted by the drugs may make a difference in identifying the role of these receptors in chemoreflex function.
In our study, we used approximately one-half of the dose of idazoxan reported previously to modulate baroreflex function (33) when microinjected into the more rostral region of the NTS. Approximately 5 min following central ␣-2 adrenergic receptor blockade, we observed a marked attenuation of all components of the arterial chemoreflex. Reflex responses returned within 90 min, suggesting that tonic activation of ␣-2 adrenoreceptors in the cNTS is important for the central processing of arterial chemoreceptor afferent inputs. The similarities between our findings and the effects observed by others on baroreflex function in the intermediate regions of the NTS (20, 33) strongly suggest that tonic activation of ␣-2 adrenoreceptors throughout the NTS may be extremely important to the initial processing of visceral afferent inputs.
We also confirmed that use of a broad-spectrum EAA receptor antagonist in the same region markedly reduced arterial chemoreflex responses. This finding is in agreement with previous reports investigating the role of EAA receptors in the NTS on chemoreflex function (36, 38) . Although reflex function was markedly attenuated following blockade of EAA receptors in the cNTS, we did not observe any significant shift in baseline pressure. Similarly, blockade of ␣-2 adrenoreceptors in the cNTS did not significantly alter baseline blood pressure. These findings suggest that tonic input from the arterial chemoreceptors does not significantly contribute to the mechanisms controlling baseline pressure in the anesthetized normotensive rat. This is in marked contrast to the 20-to 50-mmHg increase in resting pressure reported to follow ␣-2 adrenoreceptor blockade in the intermediate NTS and blockade of baroreflex function (33) .
Although blockade of EAA receptors and ␣-2 adrenergic receptors in the cNTS produced similar effects on chemoreflex function and baseline blood pressure, the two different receptor antagonists had markedly different effects on resting respiratory rate. On the one hand, EAA receptor blockade in the region of the cNTS produced a significant decrease in respiratory rate and prolongation of dEMG burst duration. In contrast, no change in resting respiratory rate was observed following ␣-2 receptor blockade. Because inspiratory burst duration is heavily influenced by input from pulmonary stretch receptors and these receptors terminate in cNTS, it is possible that the change in respiratory rate observed following EAA receptor blockade was due to a change in the central processing of these sensory afferents and a subsequent change in inputs to the respira-tory central pattern generator. Indeed, it has been shown that the termination of inspiration mediated by these receptors depends on activation of glutamate receptors in the cNTS (2) . Interestingly, the lack of influence of ␣-2 receptor blockade on baseline respiratory rate suggests the possibility that catecholamines may not be involved in the central processing pulmonary afferents. This, however, remains to be tested.
Finally, the results of the present study and other studies (20, 33) suggest that ␣-2 adrenoreceptors play a significant role in modulating sensory processing within the NTS. Despite this, the mechanisms through which ␣-2 adrenoreceptors modulate afferent processing in the NTS remain to be identified. Single-unit recording studies have demonstrated that local application of ␣-2 adrenoreceptor agonists in the cNTS typically inhibits cNTS neuronal activity (24) . Accordingly, it might be expected that application of the receptor antagonist, such as the ones used in the present study, would facilitate afferent processing. Yet, the exact opposite effect was observed on the level of the whole reflex. One possible explanation is that ␣-2 receptors are primarily located on and/or primarily modulate the function of inhibitory interneurons within the NTS. Removal of tonic suppression of these inhibitory interneurons in the presence of idazoxan would then lead to an increase in the local release of GABA, an inhibitory neurotransmitter. The resulting effect would be a marked attenuation of afferent processing within the NTS and blunting of reflex function. Although this hypothesis remains to be tested, a similar modulatory effect on GABAergic interneurons in the cNTS has been proposed to mediate the effects of serotonin, another central neuromodulator of chemoreflex function (30) . Alternatively, there is some evidence from pharmacological studies of preganglionic neurons in the spinal cord, which suggests that neurons receiving catecholaminergic inputs may contain both ␣-1 and ␣-2 adrenergic receptors, these receptors may be differentially expressed on the cell soma vs. dendritic processes, and selective activation of either receptor subtype may have opposing effects on membrane excitation (23) . Thus the discrepancy between the effects of catecholaminergic receptor activation on sensory processing in the NTS at the level of a single neuron vs. a network of neurons may simply reflect the combined influence of ␣-1 and ␣-2 receptors in this region of the brain. The role of ␣-1 receptor modulation in the cNTS on chemoreflex function remains to be tested.
In conclusion, the present study has identified for the first time the physiological effect of blockade of ␣-2 adrenoreceptors in the cNTS on arterial chemoreflex function in anesthetized rats. Pharmacological blockade of ␣-2 receptors with either the selective blocker idazoxan or yohimbine was shown to markedly attenuate the arterial chemoreflex response to KCN. The profound influence of ␣-2 adrenoreceptor blockade on chemoreceptor afferent processing at the level of the cNTS mimics the effect previously reported at the level of the intermediate NTS for baroreflex processing. These data support the hypothesis that endogenous catecholamines are integrally involved in visceral afferent processing throughout the NTS. The specific mechanism by which ␣-2 adrenoreceptors modulate chemoreceptor afferent processing in the NTS, however, remains to be addressed. Additional studies are needed to determine the influence of this neuromodulator on specific types of chemoreceptor afferent-sensitive cNTS neurons (GABAergic or glutamatergic).
Perspectives
Previous studies investigating a putative role for catecholamines in the central arterial chemoreflex pathway have identified that local levels of norepinephrine within the NTS increase threefold following prolonged exposure to hypoxia (28) . In addition, a portion of the respiratory response to long-term exposure to hypoxia has been shown to depend on the integrity central catecholaminergic inputs (1) and local destruction of neurons within the ventrolateral pons, which contains a cluster of noradrenergic neurons and markedly attenuates the sympathetic component of the arterial chemoreflex (18, 29) . Thus there is indirect evidence to support a role for central catecholamines in altered cardiorespiratory function following chronic exposure to hypoxia and possibly in the hypoxia-induced development of hypertension. The results of the present study provide a new perspective on the potential role of cNTS neurons in this ␣-2 adrenergic modulation of arterial chemoreflex function. The origin of this potentially important noradrenergic input to the cNTS, however, remains to be identified as does the possibility that other adrenoreceptor subtypes may also contribute to chemoreflex modulation in the cNTS. Finally, although we did not observe any significant changes in baseline blood pressure following acute blockade of ␣-2 adrenoreceptors in the cNTS, it remains to be determined whether chronic changes in the adrenoreceptor function in the cNTS or other regions of the brain (37) might significantly contribute to increased baseline sympathetic drive and the development and maintenance of hypertension associated with chronic exposure to episodic hypoxia.
